分子异常在MDS诊疗中的应用4.pptx

分子异常在MDS诊疗中的应用;MDS的细胞遗传学异常;MDS的分子异常;;Clinical Effect of Point Mutations in Myelodysplastic Syndromes;Clinical and biological implications of driver mutations in myelodysplastic syndromes;Landscape of genetic lesions in 944 patients with myelodysplastic syndromes;特点;?分子异常在MDS诊疗中的应用;分子异常在MDS诊断;;;克隆性造血在人群中的分布;Age-Related Clonal HematopoiesisAssociated with Adverse Outcomes;60-69y 　 5.6% 70-79y 　9.5% 80-89y 　11.7% 90-108 　 18.4%;意义不明的克隆性造血(Clonal hematopoiesis of indeterminate potential,CHIP );Somatic Mutations and ClonalHematopoiesis in Aplastic Anemia;MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined signi?cance; idiopathic cytopenias of undetermined significance (ICUS) ;体细胞突变作为MDS诊断标志的缺陷;The 2016 revision to the WHO classification of myeloid neoplasms and acute leukemia;排除诊断;分子异常在MDS分型中的意义;Clinical significance of SF3B1 mutations in myelodysplastic syndromes andmyelodysplastic/myeloproliferative neoplasms. Blood. 2011;118(24):6239-6246;The 2016 revision to the WHO classification of myeloid neoplasms and acute leukemia;;分子异常在MDS治疗中的意义;TET2突变对HMA治疗反应率增高;;Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms;;; ;;分子异常在MDS预后判断中的意义;IPSS Mutation;LR+mutation=IR-1 IR-1+mutation=IR-2;IR-2+mutation=HR ;;随着基因突变数增加，无白血病生存率渐降低，白血病转化危险增加;Somatic Mutations Predict Survival After Transplantation for MDS;;;SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts;151 92;;结语